US and EU approval for St Jude's non-rechargeable neurostimulator
This article was originally published in Clinica
St Jude Medical has launched its EonC neurostimulator in the US following FDA premarket approval (PMA) for the treatment of chronic pain. The St Paul, Minnesota firm also CE marked the product for sale in Europe, and will launch it there next week. EonC delivers mild electrical pulses to the spinal cord, interrupting or masking pain signals. It is non-rechargeable, unlike St Jude's Eon and Eon Mini devices, which can be charged in a similar way to a mobile phone. St Jude said that EonC was designed for patients who do not want to be burdened with recharging, and claims it has the greatest battery capacity of any primary cell neurostimulator.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.